July 2009 Volume 5 Number 7
Visit Nature Reviews Neurology online to browse the journal.
Now available at
http://links.ealert.nature.com/ctt?kn=67&m=33524368&r=MTc2NDUyMzIwMwS2&b=2&j=NTI2NDE5MDkS1&mt=1&rt=0
Please note that you need to be a subscriber to enjoy full text access
to Nature Reviews Neurology online. To purchase a subscription, please visit:
http://links.ealert.nature.com/ctt?kn=40&m=33524368&r=MTc2NDUyMzIwMwS2&b=2&j=NTI2NDE5MDkS1&mt=1&rt=0
Alternatively, to recommend a subscription to your library, please visit
http://links.ealert.nature.com/ctt?kn=56&m=33524368&r=MTc2NDUyMzIwMwS2&b=2&j=NTI2NDE5MDkS1&mt=1&rt=0
*********************************************************************
Nature Reviews Neurology Impact Factor: 4.339*
(*Journal Citation Reports, Thomson, 2005)
*********************************************************************
=========================== ADVERTISEMENT ===========================
Top cited articles from Journal of Cerebral Blood Flow & Metabolism (JCBFM)
at http://links.ealert.nature.com/ctt?kn=47&m=33524368&r=MTc2NDUyMzIwMwS2&b=2&j=NTI2NDE5MDkS1&mt=1&rt=0
A leading journal in the neurosciences, JCBFM provides extensive coverage
in experimental, theoretical, and clinical aspects of brain circulation,
metabolism and imaging. We invite you to read a selection of top cited
articles FREE of charge. Featured topics include: acute ischemic stroke,
brain ischemia, neurodegeneration, and flow-based vascular modeling.
Access select articles throughout the year by registering for JCBFM's
Table of Contents e-alerts.
Register online at
http://links.ealert.nature.com/ctt?kn=68&m=33524368&r=MTc2NDUyMzIwMwS2&b=2&j=NTI2NDE5MDkS1&mt=1&rt=0
=====================================================================
----------------------
RESEARCH HIGHLIGHTS
----------------------
Prion disease: Variant Creutzfeldt-Jakob disease epidemic looks increasingly
unlikely in the UK
p349 | doi:10.1038/nrneurol.2009.85
http://links.ealert.nature.com/ctt?kn=79&m=33524368&r=MTc2NDUyMzIwMwS2&b=2&j=NTI2NDE5MDkS1&mt=1&rt=0
Dementia: Cholinesterase inhibitor use link with syncope
p350 | doi:10.1038/nrneurol.2009.83
http://links.ealert.nature.com/ctt?kn=14&m=33524368&r=MTc2NDUyMzIwMwS2&b=2&j=NTI2NDE5MDkS1&mt=1&rt=0
IN BRIEF
Brain imaging | Brain imaging | Sensory systems
p350 | doi:10.1038/nrneurol.2009.88
http://links.ealert.nature.com/ctt?kn=8&m=33524368&r=MTc2NDUyMzIwMwS2&b=2&j=NTI2NDE5MDkS1&mt=1&rt=0
Multiple sclerosis: Laminins control T-cell entry into the CNS
p351 | doi:10.1038/nrneurol.2009.76
http://links.ealert.nature.com/ctt?kn=65&m=33524368&r=MTc2NDUyMzIwMwS2&b=2&j=NTI2NDE5MDkS1&mt=1&rt=0
Neurodegenerative disease: Antisense targets faulty Huntington allele
p351 | doi:10.1038/nrneurol.2009.77
http://links.ealert.nature.com/ctt?kn=26&m=33524368&r=MTc2NDUyMzIwMwS2&b=2&j=NTI2NDE5MDkS1&mt=1&rt=0
Peripheral neuropathies: Less sweat, more neuropathy
p352 | doi:10.1038/nrneurol.2009.78
http://links.ealert.nature.com/ctt?kn=39&m=33524368&r=MTc2NDUyMzIwMwS2&b=2&j=NTI2NDE5MDkS1&mt=1&rt=0
Stroke: Patients on statins have better outcome of intracerebral hemorrhage
p352 | doi:10.1038/nrneurol.2009.86
http://links.ealert.nature.com/ctt?kn=53&m=33524368&r=MTc2NDUyMzIwMwS2&b=2&j=NTI2NDE5MDkS1&mt=1&rt=0
Altered motion perception in autism
p353 | doi:10.1038/nrneurol.2009.87
http://links.ealert.nature.com/ctt?kn=36&m=33524368&r=MTc2NDUyMzIwMwS2&b=2&j=NTI2NDE5MDkS1&mt=1&rt=0
Parkinson disease: New genetic risk factor for sporadic PD
p354 | doi:10.1038/nrneurol.2009.79
http://links.ealert.nature.com/ctt?kn=78&m=33524368&r=MTc2NDUyMzIwMwS2&b=2&j=NTI2NDE5MDkS1&mt=1&rt=0
Parkinson disease: Intrajejunal duodopa improves nonmotor symptoms
p354 | doi:10.1038/nrneurol.2009.84
http://links.ealert.nature.com/ctt?kn=44&m=33524368&r=MTc2NDUyMzIwMwS2&b=2&j=NTI2NDE5MDkS1&mt=1&rt=0
----------------------
NEWS AND VIEWS
----------------------
Milestone: Neurology's growth factor: 100 years of Rita Levi-Montalcini
Jeroen J. G. Geurts
p355 | doi:10.1038/nrneurol.2009.91
On Wednesday 22 April 2009, Rita Levi-Montalcini, Nobel Prize laureate
and discoverer of the first neural growth factor, turned 100 years old.
Her scientific work drastically changed basic neuroscience and could have
important implications for the treatment of neurological disorders.
http://links.ealert.nature.com/ctt?kn=72&m=33524368&r=MTc2NDUyMzIwMwS2&b=2&j=NTI2NDE5MDkS1&mt=1&rt=0
Epilepsy: Is localization-related epilepsy a progressive disorder? Maybe...
Ruben Kuzniecky, Thomas Thesen and Orrin Devinsky
p356 | doi:10.1038/nrneurol.2009.82
The issue of whether progressive brain injury occurs in pharmacoresistant
epilepsy remains important and controversial. A combined longitudinal and
cross-sectional MRI study, in which an automated method was used to measure
cortical thickness, has demonstrated accelerated brain atrophy in patients
with chronic epilepsy.
http://links.ealert.nature.com/ctt?kn=10&m=33524368&r=MTc2NDUyMzIwMwS2&b=2&j=NTI2NDE5MDkS1&mt=1&rt=0
Dementia: What is behavioral variant frontotemporal dementia?
Murray Grossman
p358 | doi:10.1038/nrneurol.2009.81
In an era of etiology-specific therapies, defining the criteria for
behavioral variant frontotemporal dementia is essential. How do we determine
whether bad manners, laziness, or unsolicited friendliness represents the
earliest presentation of this condition? Diagnostic criteria are being
actively evaluated to help establish a foundation for diagnostic decisions
regarding this and other neurodegenerative diseases.
http://links.ealert.nature.com/ctt?kn=23&m=33524368&r=MTc2NDUyMzIwMwS2&b=2&j=NTI2NDE5MDkS1&mt=1&rt=0
Pain: Clinical pain assessment: from bedside to better treatment
Gunnar Wasner and Ralf Baron
p359 | doi:10.1038/nrneurol.2009.93
Successfully treating chronic pain is challenging, as patients respond
heterogeneously to analgesic treatments. Such variation in response can
be attributed to differing underlying pain-generating mechanisms. A novel
clinical bedside test that identifies distinct pain phenotypes might help
deliver more-effective mechanism-based treatment strategies.
http://links.ealert.nature.com/ctt?kn=66&m=33524368&r=MTc2NDUyMzIwMwS2&b=2&j=NTI2NDE5MDkS1&mt=1&rt=0
Alzheimer disease: Hippocampal volume loss and Alzheimer disease progression
Wiesje M. van der Flier and Philip Scheltens
p361 | doi:10.1038/nrneurol.2009.94
The progression of Alzheimer disease might be monitored by measuring the
rate of hippocampal volume loss by means of MRI. Research suggests that
a reduction in hippocampal volume can be detected over a period as short
as 6 months, and that such volume loss is associated with cognitive decline
and other indicators of Alzheimer disease neuropathology.
http://links.ealert.nature.com/ctt?kn=73&m=33524368&r=MTc2NDUyMzIwMwS2&b=2&j=NTI2NDE5MDkS1&mt=1&rt=0
----------------------
REVIEWS
----------------------
Management of new-onset epilepsy in the elderly
Amir M. Arain and Bassel W. Abou-Khalil
p363 | doi:10.1038/nrneurol.2009.74
New-onset epilepsy in elderly individuals presents important diagnostic
and therapeutic challenges for the clinician. Arain and Abou-Khalil highlight
the conditions that should be considered in the differential diagnosis,
and discuss the factors that need to be taken into account when devising
an appropriate drug regimen, including age-related changes in pharmacokinetic
factors, potential drug interactions, and adverse-effect profiles.
Abstract: http://links.ealert.nature.com/ctt?kn=5&m=33524368&r=MTc2NDUyMzIwMwS2&b=2&j=NTI2NDE5MDkS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=75&m=33524368&r=MTc2NDUyMzIwMwS2&b=2&j=NTI2NDE5MDkS1&mt=1&rt=0
Critical illness polyneuropathy and myopathy in the intensive care unit
Wolfgang Zink, Rainer Kollmar and Stefan Schwab
p372 | doi:10.1038/nrneurol.2009.75
Improvements in the survival of critically ill patients over the past few
decades have led to an increased incidence of acquired muscular weakness
in intensive care units. Zink and colleagues review the clinical and
diagnostic features of critical illness polyneuropathy and myopathy and
discuss preventive and therapeutic approaches to these severe and costly
medical complications.
Abstract: http://links.ealert.nature.com/ctt?kn=77&m=33524368&r=MTc2NDUyMzIwMwS2&b=2&j=NTI2NDE5MDkS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=49&m=33524368&r=MTc2NDUyMzIwMwS2&b=2&j=NTI2NDE5MDkS1&mt=1&rt=0
Epileptogenesis in the immature brain: emerging mechanisms
Sanjay N. Rakhade and Frances E. Jensen
p380 | doi:10.1038/nrneurol.2009.80
The developing brain is especially prone to seizure activity, and population
studies have shown that seizure incidence peaks during the first month
of life. Research into the factors responsible for this enhanced seizure
susceptibility could yield potential therapeutic targets to prevent
epileptogenesis and provide biomarkers to identify individuals who are
at heightened risk of developing epilepsy.
Abstract: http://links.ealert.nature.com/ctt?kn=1&m=33524368&r=MTc2NDUyMzIwMwS2&b=2&j=NTI2NDE5MDkS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=48&m=33524368&r=MTc2NDUyMzIwMwS2&b=2&j=NTI2NDE5MDkS1&mt=1&rt=0
Lumbar spinal stenosis: syndrome, diagnostics and treatment
Eberhard Siebert, Harald Pruss, Randolf Klingebiel, Vieri Failli,
Karl M. Einhaupl and Jan M. Schwab
p392 | doi:10.1038/nrneurol.2009.90
In lumbar spinal stenosis (LSS), narrowing of the spinal canal leads to
neural compression and, frequently, pain in the lower back. LSS has become
the most common reason for lumbar spine surgery, partly reflecting the
elevated demand for mobility and flexibility in the aging population. In
this article, Siebert et al. review the underlying pathophysiology of LSS,
and discuss how to diagnose and treat the condition.
Abstract: http://links.ealert.nature.com/ctt?kn=41&m=33524368&r=MTc2NDUyMzIwMwS2&b=2&j=NTI2NDE5MDkS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=60&m=33524368&r=MTc2NDUyMzIwMwS2&b=2&j=NTI2NDE5MDkS1&mt=1&rt=0
=====================================================================
You have been sent this Table of Contents Alert because you have opted
in to receive it. You can change or discontinue your e-mail alerts at any
time, by modifying your preferences on your nature.com account at:
http://links.ealert.nature.com/ctt?kn=27&m=33524368&r=MTc2NDUyMzIwMwS2&b=2&j=NTI2NDE5MDkS1&mt=1&rt=0
(You will need to log in to be recognised as a nature.com registrant).
For further technical assistance, please contact our registration department:
registration@nature.com
For print subscription enquiries, please contact our subscription department:
subscriptions@nature.com
For other enquiries, please contact our customer feedback department:
feedback@nature.com
Nature Publishing Group | 75 Varick Street, 9th Floor | New York |
NY 10013-1917 | USA
Nature Publishing Group's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne -
San Diego - San Francisco - Washington - New York - Boston
(c) Copyright 2009 Nature Publishing Group
=====================================================================
